Tag: Genentech

Lonza to acquire Genentech’s biologics manufacturing facility in Vacaville for $1.2bn

businessnewstoday- March 20, 2024

In a strategic move that significantly escalates its capacity in the biologics manufacturing landscape, Lonza, a key global player in manufacturing for the pharmaceutical, biotech, ... Read More

FDA approves Genentech’s Xolair for food allergies: A new horizon in allergy treatment

businessnewstoday- February 17, 2024

The U.S. Food and Drug Administration (FDA) has approved Xolair (omalizumab) for reducing allergic reactions, including anaphylaxis, that may occur with accidental exposure to foods ... Read More

Genentech’s Phase 3 study of inavolisib in breast cancer reveals positive results

businessnewstoday- December 9, 2023

Genentech, part of the Roche Group, has presented compelling results from the Phase III INAVO120 study, evaluating the effectiveness of inavolisib in combination with palbociclib ... Read More

Genentech’s Alecensa shows promise in Phase III ALINA study for early-stage ALK-positive NSCLC

businessnewstoday- September 3, 2023

Genentech, a Roche Group member, has announced positive results from its Phase III ALINA study evaluating Alecensa (alectinib), setting a new standard for treating early-stage ... Read More

Genentech bags Lunsumio FDA approval for R/R follicular lymphoma

Raghuram Kadari- December 28, 2022

Lunsumio FDA approval : Genentech, a subsidiary of the Roche Group, has secured the approval of the US Food and Drug Administration (FDA) for Lunsumio ... Read More

Genentech gets Actemra FDA approval for COVID-19 in hospitalized adults

Raghuram Kadari- December 26, 2022

Actemra FDA approval : Genentech, a subsidiary of Roche, has received the approval of the US Food and Drug Administration (FDA) for Actemra (tocilizumab) intravenous ... Read More

FDA accepts BLA for Lucentis referencing ophthalmology biosimilar SB11

pharmanewsdaily- November 19, 2020

Samsung Bioepis and Biogen said that the US Food and Drug Administration (FDA) has accepted for review the biologics license application for SB11, a proposed ... Read More

UCB signs $2bn worth deal with Roche for AD drug candidate UCB0107

pharmanewsdaily- July 29, 2020

Belgian pharma company UCB has signed a global exclusive license deal worth up to $2 billion for its Alzheimer's Disease drug candidate (AD drug candidate) ... Read More

Blueprint Medicines strikes $1.7bn worth deal with Roche for pralsetinib

pharmanewsdaily- July 15, 2020

Swiss pharma giant Roche and US precision therapy company Blueprint Medicines have entered into a worldwide licensing and collaboration deal potentially worth up to $1.703 ... Read More

Clover Health launches chronic diseases-focused Clover Therapeutics

pharmanewsdaily- July 10, 2019

California-based healthcare company Clover Health has launched a new research subsidiary, called Clover Therapeutics, which will focus on developing drugs for older adults for the ... Read More